Among the fusions that have not been previously described in cancer, the majority can be attributed to new partners of already known fusion genes in B-ALL or other hematological malignancies such as ST3GAL1 or P2RY8 (Figure 1C) (Data file 3). This evidence concerns the gene ST3GAL1 and hematologic disorder.